Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 14, 2020
Reporting Period: Event-based report regarding a specific grant award received on September 14, 2020.
Key Financial Metrics
This filing does not report standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a non-dilutive grant award.
| Grant Component | Amount | Year |
|---|---|---|
| Initial Award | $739,739 | 2020 |
| Contingent Award | $1,210,680 | 2021 |
| Contingent Award | $995,947 | 2022 |
| Total Potential Grant | $2,946,366 | 2020-2022 |
Material Changes
The material event reported is the award of a grant by the National Institutes of Health (NIH) to support clinical research. This represents a new source of non-dilutive funding for the Company's operations.
Outlook, Management Commentary, and Risks
- Grant Purpose: The funding will support a Phase 2 study of the Company's candidate drug, XPro1595, in patients with treatment-resistant depression.
- Source: National Institute of Mental Health (NIMH), part of the NIH, under Award Number R44MH125480.
- Conditions: Future disbursements for 2021 and 2022 are subject to the terms of the Grant agreement.
- Disclaimer: The content of the research is the sole responsibility of the Company and does not necessarily represent the official views of the NIH.
Investor Verification Checklist
- Verify the specific terms and milestones required to unlock the 2021 and 2022 grant installments.
- Confirm the status and timeline of the Phase 2 study for XPro1595 in treatment-resistant depression.
- Review the attached press release (Exhibit 99.1) for additional details on the grant's impact on the Company's cash runway.
- Monitor future filings for actual disbursement dates and amounts received against the projected schedule.